Skip to main
OPK
OPK logo

OPKO Health (OPK) Stock Forecast & Price Target

OPKO Health (OPK) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

OPKO Health Inc has strategically focused its business on drug development, which is expected to enhance its financial position and strengthen its balance sheet by streamlining operations following recent divestitures. The company reported a total revenue of $183.6 million for Q4 2024, reflecting a year-over-year growth of 0.9%, which surpassed expectations and demonstrates resilience in its financial performance. Additionally, improvements in BioReference's productivity and the management's commitment to achieving profitability by 2025 indicate a positive trajectory for the company's diagnostics segment, further supporting an optimistic outlook for OPKO Health's stock.

Bears say

OPKO Health Inc. reported a significant 17% year-over-year decline in diagnostics services revenue, totaling $103.1 million, largely attributed to reduced clinical test volume after the sale of certain BioReference assets. The company's overall revenue for the full year 2024 also decreased by 17% year-over-year to $713.1 million, with pharmaceutical products revenue falling by 13% to $37.4 million due to unfavorable foreign currency exchange rates. The company faces multiple risks, including slow growth in the diagnostics segment, challenges in developing new pharmaceuticals, and volatility in sales from emerging markets, which contribute to a negative outlook.

OPKO Health (OPK) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OPKO Health (OPK) Forecast

Analysts have given OPKO Health (OPK) a Buy based on their latest research and market trends.

According to 11 analysts, OPKO Health (OPK) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OPKO Health (OPK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.